Clinical Trial Update: An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab with BMS-986205 versus EXTREME in first-line recurrent/metastatic squamous cell carcinoma of the head and neck was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• BMS-986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Head and Neck Cancer | Phase 3 | Status: WITHDRAWN